.
MergerLinks Header Logo

Announced

Completed

Pacira BioSciences completed the acquisition of Flexion Therapeutics for $630m.

Financials

Edit Data
Transaction Value£462m
Consideration TypeCash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Single Bidder

biopharmaceutical company

Friendly

United States

Domestic

Private

Pharmaceuticals

Majority

Acquisition

Completed

Synopsis

Edit

Pacira BioSciences, a pharmaceutical company, completed the acquisition of Flexion Therapeutics, a biopharmaceutical company, for $630m including debt. “This combination with Pacira offers Flexion stakeholders excellent prospects for value creation, particularly as the contingent value rights provide the opportunity to continue to benefit from the ongoing success of Flexion’s products and programs. I’d like to thank all of our employees - past and present - for their extraordinary commitment and superb contributions that have translated into ZILRETTA, a medicine that matters, getting to increasing numbers of patients in need and to a pipeline of potentially transformative medicines,” Michael Clayman, Flexion Co-Founder and CEO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US